Hans Gangeskar, CEO of Overture Life [Composite image; Original photo: Hans Gangeskar/LinkedIn]
Palo Alto, California-based Overture Life—the company behind “the world’s first babies born from robotic fertilization and robotic egg freezing”—has opened its U.S. clinical operations headquarters in Dallas The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos, with machine-learning support. Overture says this will give fertility teams “objective data to inform embryo selection without a biopsy.”
The company’s first dedicated U.S. laboratory, the facility in the Bogart Building at 4621 Ross Avenue will help the company accelerate deployment of its automated IVF platforms, which currently operate in clinics across Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey.
Overture was originally founded in Madrid, Spain, in 2017.
“This Dallas hub bridges our European manufacturing and research operations with North American markets,” CEO Hans Gangeskar said in a statement. “The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.”
Freezing eggs with ‘robotic precision’
Hafsa Irfan
The company said its new Dallas facility will anchor its U.S. expansion as demand builds for its DaVitri automated egg-freezing system. The platform freezes eggs with robotic precision, Overture said, achieving a 12% improvement in egg survival rates “while allowing clinics to process three times the number of procedures without adding staff.”
Hafsa Irfan is head of clinical operations for the Dallas facility and will be overseeing the lab’s scientific build-out and operations and metabolomics assay optimization.
“The infrastructure we’re establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,” Irfan said in a statement.
Dallas facility a ‘multi-million-dollar’ investment
Overture said the lab equipment and infrastructure at its new Dallas facility represent “a multi-million-dollar investment” in advanced technical capabilities.
The facility will focus on non-invasive embryo testing that provides fertility teams with molecular data to guide treatment decisions—without requiring embryo biopsies. The facility’s design accommodates expanded lab services and continued advancement of AI-driven automation protocols, the company said, including building “a continuously learning, regulated automation layer,” which is the infrastructure that makes AI-driven IVF reproducible, measurable, and clinically validated.
Selecting Dallas for its ‘growing biomedical workforce’ and more
The company said Dallas emerged as the location choice due to its concentration of life sciences companies, proximity to research institutions including UT Southwestern Medical Center, and growing biomedical workforce. It noted that North Texas’ biomedical sector employs over 27,000 professionals across 850 companies—with particular strength in medical device development and clinical research.
Overture said it will be hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at its Dallas facility. In addition, the Dallas lab will coordinate with Overture’s R&D operations in Spain and the company’s growing network of clinical partners.
The Dallas lab is joining Overture’s facilities in Spain amid the company’s buildout of infrastructure to meet growing demand. Overture says its DaVitri system’s European pre-order waitlist, launched in September, “filled within weeks” as clinics sought automation systems with “documented healthy births” and peer-reviewed clinical outcomes.
Platform standardizes the egg freezing process
Overture said its automation portfolio addresses the most technically demanding procedures in IVF. In 2024, the company’s ICSI.A system “achieved the world’s first babies born from robotic sperm injection,” Overture said. Its DaVitri platform “standardizes” the egg freezing process, which typically requires years of specialized training.
Together, these systems help laboratories deliver consistent results, Overture said, while reducing the physical strain on embryologists who perform thousands of precise manual procedures annually.
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
The southern half of Dallas County is home to just over 1.05 million residents. That’s about 40% of the total number of people who call Dallas County home—and roughly 200,000 more than the entire population of San Francisco. Coupled with the fact that Dallas-Fort Worth is emerging as a top life science market, as documented in a 2023 CBRE report, you can see why the DeSoto Development Corp. is including an 80-acre Life Sciences Innovation Core among its major projects. “In terms of economic development, research shows that it’s more effective when it happens regionally,” says Matt Carlson, DDC’s chief…
-
The North Texas-based precision oncology firm raised $494 million in its IPO. Founder David Halbert is now a newly minted biotech billionaire worth an estimated $3.3 billion, Forbes reports.
-
At its Dallas Design District grand opening, Koya Medical marked the official move of its headquarters from California—bringing with it a wearable alternative to wall-powered compression therapy for vascular patients. “This is something that is different from anything that is out there,” says vascular surgeon and new CMO Tom Maldonado.
-
Bridging science and law, Westcott will drive MWM’s Life Sciences Practice into the next frontier of biotech and MedTech innovation.
-
With $1.86 billion raised since 2018 and recent product launches, the North Texas life science company founded in 2008 is preparing for a public debut on the Nasdaq Global Select Market, following a $168 million growth capital round in April.